Michael focuses his practice on complex corporate transactions, with particular emphasis on representing issuers and investment banks in the life sciences and technology sectors in public and private capital markets deals, including initial public offerings, high-yield bond offerings, private placements, ATMs and specialty finance transactions involving SPACs and REITs. He regularly counsels public company clients and their advisors on issues including securities law compliance, corporate governance practices and disclosure obligations.

Prior to joining Fenwick, Michael worked at a leading global law firm. He also previously worked in the capital markets legal groups at BofA Securities (formerly Bank of America Merrill Lynch) and Morgan Stanley.

Read More

  • Representative Equity Offerings
    • bluebird bio’s* $500M follow-on offering
    • Cerulean Pharma’s* $60M initial public offering
    • Change Healthcare’s $640.7M initial public offering
    • Clementia Pharmaceuticals’* $120M initial public offering and $70.26M follow-on offering
    • Dimension Therapeutics’* $71.5M initial public offering
    • Habit Restaurants on its $90M initial public offering and $154.8M follow-on offering
    • Idera Pharmaceuticals’* $50M initial public offering
    • Karyopharm Therapeutics’* $108.8M initial public offering
    • Kiniksa Pharmaceuticals’* $152.6M initial public offering
    • LogicBio Therapeutics on its $70M initial public offering and $50M follow-on offering
    • Madrigal Pharmaceuticals’* $129.42M follow-on offering
    • Moderna’s* $604.3M initial public offering and $1.34B follow-on offering
    • Momenta Pharmaceuticals’* $225M initial public offering
    • nCino’s* $250M initial public offering
    • Planet Fitness on its $1.275B securitized financing facility transaction
    • Proteostasis Therapeutics’* $50M initial public offering
    • Quanterix’s* $64.13M initial public offering and $60M follow-on offering
    • Radius Health’s* $300M follow-on offering
    • Relay Therapeutics’* $400M initial public offering
    • Sarepta Therapeutics on its $350M follow-on offering
    • Seres Therapeutics’* $225.75M follow-on offering
    • Sixth Street Specialty Lending’s* $86.6M follow-on offering
    • Surgery Partners on its $271.2M initial public offering
    • TherapeuticsMD’s* $125M follow-on offering
  • Representative High Yield Bond Offerings
    • Karyopharm Therapeutics* on its $150M convertible senior notes offering
    • NFP on its $200M debt financing
  • Representative SPAC Transactions
    • Nextdoor in its business combination with Khosla Ventures Acquisition Co. II (pending)
    • Altimeter Growth on its $450M initial public offering
    • Ares Acquisition’s* $870M initial public offering
    • Ascendant Digital Acquisition’s* $360M initial public offering
    • Carney Technology Acquisition’s* $350M initial public offering
    • Fortress Capital Acquisition’s* $350M initial public offering
    • Jiya Acquisition’s* $100M initial public offering
    • Juniper Industrial Holding’s $300M initial public offering
    • Montes Archimedes Acquisition’s* $400M initial public offering
    • Reinvent Technology Partners’* $600M initial public offering
    • Reinvent Technology Partners 2’s* $200M initial public offering
    • Sustainable Development Acquisition I in its $275M initial public offering
    • TCW Special Purpose Acquisition’s $450M initial public offering

    *Representing the Representatives on behalf of the Underwriters/Initial Purchasers, including such investment banks as Goldman Sachs, Morgan Stanley, J.P. Morgan, Barclays, BofA Securities, Citigroup, Cowen, Credit Suisse, Deutsche Bank and SVB Leerink, among others.

Education & Admissions

J.D., cum laude, Brooklyn Law School

B.S., Psychology, Union College

Admitted to practice in New York

Login

Don’t have an account yet?

Register